NASDAQ: BLTE - Belite Bio, Inc

Altı ay boyunca karlılık: +42.68%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Belite Bio, Inc

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients.

daha fazla ayrıntı
The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2022-04-29
ISIN US07782B1044
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://belitebio.com
Цена ао 65.21
Günlük fiyat değişimi: +0.0598% (66.85)
Haftalık fiyat değişimi: -0.5797% (67.28)
Aylık fiyat değişimi: +20.52% (55.5)
3 ayda fiyat değişimi: +7.89% (62)
Altı ayda fiyat değişimi: +42.68% (46.88)
Yıllık fiyat değişimi: +74.33% (38.37)
Yılbaşından bu yana fiyat değişimi: +6.01% (63.1)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 13.5 1
P/E 0 0
EV/EBITDA -36.24 0
Toplam: 1.13

Yeterlik

İsim Anlam Seviye
ROA, % -33.42 0
ROE, % -34.98 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0283 10
Toplam: 9

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 453.14 10
karlılık EPS, % 398.1 10
Toplam: 8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Armistice Capital, LLC 36000 0.12
Morgan Stanley 22421 0.08
State Street Corporation 17557 0.06
Cubist Systematic Strategies, LLC 16882 0.06
Marshall Wace LLP 16011 0.05
JP Morgan Chase & Company 14267 0.05
Point72 Asset Management, L.P. 7700 0.03
Geode Capital Management, LLC 6700 0.02
Jump Financial, LLC 5200 0.02
Renaissance Technologies, LLC 4900 0.02

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
Virtus LifeSci Biotech Clinical Trials ETF 0.76712 63.04 0.33
SPDR S&P Emerging Markets Small Cap ETF 0.03878 5.46 3.03583
SPDR S&P China ETF 0.02029 17.02 3.40103
SPDR Portfolio Emerging Markets ETF 0.00475 11.59 3.1879
0.2124.282.49



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO N/A 1979 (46 yıllar)
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director N/A 1985 (40 yıllar)
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer N/A 1967 (58 yıllar)
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board

Adres: United States, San Diego. CA, 12750 High Bluff Drive - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://belitebio.com